“At this point in the business cycle, the playbook says you have to go with more tangible companies that make real things and generate real profits,” Cramer said last week on CNBC.
One company he feels fits that bill is Fortune 100 mainstay Honeywell. (The company was ranked 94 in 2021.)
As a global industrial conglomerate, Honeywell provides an attractively diversified mix of services and products that range from aerospace and building technologies to safety and productivity solutions.
Despite a snarled global supply chain and decreased demand from its deep-pocketed airline customers, Q3 2021 saw Honeywell increase sales by 8 per cent year over year. Earnings per share increased by 29 per cent over the same period.
Improve your financial well-being
Bausch Health Companies (BHC)
Bausch Health is a Canadian pharmaceutical company that develops, manufactures and markets pharma products and branded generic drugs that target a wide variety of health disorders.
Pharma and healthcare companies are always intriguing plays during times of high inflation, as their products remain in demand even if prices rise. The same is true of farmland.
Cramer, however, is most excited by the fact that Bausch plans on breaking itself into three separate entities: eye health, medical aesthetics and pharmaceuticals.
“I like a big breakup story,” he said during a recent episode of Halftime Report. “Among planned splits at Johnson & Johnson, General Electric and Bausch, I like Bausch Health as the best breakup.”
Bausch’s stock has risen just under 15 per cent in the past 12 months.
Chevron is looking pretty good.
America’s second largest oil company continues to benefit from the ongoing inflation-driven rally in energy prices. But it also plans on investing a gargantuan sum of money into its renewable natural gas and hydrogen businesses — US$10 billion by 2028 — that should keep the company relevant for decades to come.
Chevron had an expectation-topping Q3 last year: US$6.1 billion in earnings, US$5.6 billion in debt reduction and US$2.6 billion in dividends paid out to investors.
The company’s stock is up over 30 per cent in just the last four months. It could go even higher.
“I like Chevron because I just think that oil is still undervalued even after last year,” Cramer said.
Wealthsimple x MoneyWise
Eli Lilly (LLY)
Pharma giant Eli Lilly expects the sale of COVID antibody-based treatments to help it make a projected US$28 billion in sales for 2021, but the company is also making progress with its experimental Alzheimer’s drug, donanemab.
In June, the Food and Drug Administration designated donanemab a “breakthrough therapy” based on preliminary clinical evidence. That means the FDA will expedite the drug’s review. A decision regarding the drug’s approval is expected in the second half of 2022.
A bet on Eli Lilly isn’t simply a speculative play based on new drugs. The company’s stock is up more than 215 per cent over the last five years — a very lucrative pickup, especially if you had invested using no-commission investment apps.
More from MoneyWise
- Rick Rule: Your Cash Savings Will Be Crucial During a 'Dramatic Reckoning'
- Meet the Millennials Who Are Turning Their Houseplants Into Investments
- With Interest Rates About to Rise, Here Are the Debts to Pay Off First
You're 5 minutes away from the best mortgage
Searching for your perfect mortgage shouldn’t be hard.
Homewise is an online brokerage that will negotiate on your behalf with more than 30 big banks and other lenders, completely free, and it only takes five minutes to apply.
If you're in the market for a new mortgage, or if you're looking to refinance before interest rates rise again, go to Homewise now and answer a few simple questions to get started.